Clinical Trial Detail

NCT ID NCT02651662
Title Study of REGN2810 and REGN1979 in Patients With Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Regeneron Pharmaceuticals
Indications

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

Cemiplimab

REGN1979 + REGN2810

Age Groups: adult senior

No variant requirements are available.